NEJM – Mogamulizumab (Anti-CCR4) in HTLV-1–Associated Myelopathy

felipebatalini

Hematology and Oncology fellow at Beth Israel Deaconess Medical Center, Harvard Medical School.

You may also like...

Leave a Reply

%d bloggers like this: